Cargando...
The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy
Statins (HMG-CoA reductase inhibitors) lower low-density lipoprotein cholesterol (LDL-C) and prevent cardiovascular disease. However, there is wide individual variation in LDL-C response. Drugs targeting proprotein convertase subtilin/kexin type 9 (PCSK9) lower LDL-C and will be used with statins. P...
Gardado en:
| Publicado en: | Pharmacogenomics J |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4995153/ https://ncbi.nlm.nih.gov/pubmed/26902539 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tpj.2016.3 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|